Found 138 clinical trials
The study will examine the effects that Metformin Hydrochloride has on Prostate Specific Antigen levels in men with Prostate Cancer.
The study will examine the effects that Metformin Hydrochloride has on Prostate Specific Antigen levels in men with Prostate Cancer.
- 70 views
- 23 Nov, 2020
- 1 location
A multicenter clinical study of the Sonablate® 500 (Sonablate) for the TreAtment of locally Recurrent prostate cancer with HIFU(STAR Trial)
A multicenter clinical study of the Sonablate® 500 (Sonablate) for the TreAtment of locally Recurrent prostate cancer with HIFU(STAR Trial)
- 229 views
- 25 Mar, 2021
- 1 location
PSMA-PET Registry for Recurrent Prostate Cancer (PREP)
This study aims to institute a province-wide registry leveraging the availability of a new Positron Emission Tomography tracer, [18F]-DCFPyL and PET expertise across Ontario centers to improve our ability to characterize patterns of recurrence and personalize therapies in men with recurrent prostate cancer after primary treatment.
- 108 views
- 15 Feb, 2022
- 6 locations
REGN4336 (a PSMAXCD3 Bispecific Antibody) Administered Alone or in Combination With Cemiplimab in Adult Male Patients With Metastatic Castration-Resistant Prostate Cancer
> To assess preliminary anti-tumor activity of REGN4336 as monotherapy or in combination with cemiplimab as measured by prostate specific antigen (PSA) decline To evaluate
- 4 views
- 10 Aug, 2022
- 7 locations
Radium-223 in Biochemically Recurrent Prostate Cancer
prostate cancer and induced immune changes earlier in the disease when the cancer is only detectable by prostate specific antigen (PSA) in the blood. Objective To
- 0 views
- 08 Aug, 2022
- 1 location
Partial Prostate Salvage High Dose Rate Brachytherapy (SalvageHDR)
A dose-response relationship for radiation in the management of prostate cancer is well established. Local recurrence of prostate cancer after external beam radiotherapy occurs in at least 40% of patients treated because of inability to deliver sufficient dose through external beam techniques. These patients respond well to re-irradiation using brachytherapy …
- 4 views
- 25 Feb, 2022
- 1 location
Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer
The objective of this study is to determine the maximum safe dose of Ra-223 in combination with fractionated (split doses) docetaxel when given to subjects and to determine the best administering dose. The study will look at side effects that may happen while taking the combination treatment. A total of …
- 8 views
- 10 Mar, 2022
- 4 locations
18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies
This is a pilot phase 2 single-arm study, of men with metastatic castration-resistant prostate cancer (mCRPC). Patients will be treated with any of the approved life-prolonging therapies: abiraterone 1000 mg daily plus prednisone 5 mg (or dexamethasone 0.5 mg) daily, enzalutamide 160 mg daily, or docetaxel 50 mg/m2 every two …
- 0 views
- 21 Oct, 2021
- 1 location
18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy
Background Identifying medium- and high-risk prostate cancer early may allow for treatments to work. But identification can be hard. Researchers want to see if a radiotracer used during PET scans can help. Objective To test how an imaging agent called 18F-DCFPyL detects response to standard prostate cancer treatment. Eligibility People …
- 0 views
- 27 Jul, 2022
- 1 location
The Wolverhampton Assessment Tool a Tool for Patient-reported Wellbeing in the Context of Prostate Cancer
This is a study of the Wolverhampton Assessment Tool (WATapp), a five-item questionnaire for patients with advanced or metastatic prostate cancer to say how they feel normally in terms of pain, urinary frequency, eating, and tiredness. It is widely recognised that patient-reported outcomes give a measure of overall effect of …
- 0 views
- 10 Oct, 2021
- 1 location